Physician profile
David A Johnson
NPI 1306039615
$6,974.88
in general payments reported to CMS, 2019-2025
50 companies · $664 in 2025
The $664 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $809 · 2021: $1,733 · 2022: $1,214 · 2023: $1,253 · 2024: $769 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,686.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $855.47 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $682.15 | 2019-2025 | |
| Abbvie INC. | $601.69 | 2021-2025 | |
| Novo Nordisk INC | $517.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $423.15 | 2019-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $396.20 | 2020-2023 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $330.47 | 2019-2024 | Airsupra |
| Amgen INC. | $320.17 | 2019-2024 | Prolia, Evenity, Otezla |
| Corium, LLC | $274.08 | 2022-2024 | Azstarys |
| Amarin Pharma, INC. | $245.31 | 2019-2022 | |
| Lilly USA, LLC | $232.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $205.30 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $194.44 | 2019-2023 | Steglatro, Segluromet, Steglujan |
| Supernus Pharmaceuticals, INC. | $152.25 | 2021-2022 | |
| Shire North American Group INC | $122.47 | 2019 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.